Pfizer's RSV acquisition target is Novo Ventures portfolio company

Reviral, which Pfizer intends to acquire in a deal that could total USD 525m, has received several investments from Novo Ventures.
Photo: Novo Holdings / PR
Photo: Novo Holdings / PR

Pfizer has entered into an acquisition agreement with London based Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV), in a deal that could reach USD 525m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading